Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewM-6434
Discontinued Product
0461 has been discontinued.
View all Adrenergic α<sub>1</sub> Receptors products.
说明： a1 agonist
化学名： 2-[(5-Chloro-2-methoxyphenyl)azo]-1H-imidazole
生物活性 for M-6434
An α1-agonist; a potent orally active hypertensive.
技术数据 for M-6434
| 分子量 | 236.66 |
| 公式 | C10H9CIN4O |
| 储存 | Store at RT |
| CAS Number | 77636-92-1 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
产品说明书 for M-6434
分析证书目前不在网上提供。
请联系客户服务
请联系客户服务
参考文献 for M-6434
参考文献是支持产品生物活性的出版物。
Dabasaki et al (1992) Antihypotensive effects of M6434, an orally active alpha-1-adrenoceptor agonist in rats. Jpn.J.Pharmacol. 59 145 PMID: 1279249
Ohnish (1981) Pharmacological properties of 2-[(5-chloro-2-methoxyphenyl)azo]-1H-imidazole (M6434). Arzneimittelforschung 9 1425 PMID: 7197948
Tsuchid (1986) Effects of mido. on experimentally-induced postural hypotension in dogs. Arzneimittelforschung 12 1748 PMID: 2436631
按产品操作查看相关产品
关键词: M-6434, M-6434 supplier, An, a1-agonist;, a, potent, orally, active, hypertensive., Adrenergic, Alpha-1, Receptors, 0461, Tocris Bioscience
M-6434 的评论
目前没有该产品的评论。 Be the first to review M-6434 and earn rewards!
Have you used M-6434?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.